文献速递中枢神经肿瘤放疗放疗物理与技术

胶质母细胞瘤患者大脑皮质剂量保护:IMRT与稳健治疗计划的比较

Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning.
PubMed 文献 · Radiat Oncol · 2018-02-06

该计划研究比较了经典IMRT与稳健治疗计划在胶质母细胞瘤患者中实施皮质剂量保护的效果,发现两种技术均能显著减少接受28.6 Gy以上剂量的大脑皮质体积,且不损害周围危及器官;稳健计划在靶区周围提供更锐利的剂量梯度,皮质保护更优。

要点

  • 皮质剂量约束可显著降低大脑皮质接受28.6 Gy以上剂量的体积,且不损害危及器官。
  • IMRT平均减少超过阈值剂量体积19%,稳健治疗计划减少16%。
  • 稳健计划靶区周围剂量梯度更锐利(3–6%),皮质保护优于IMRT。

核心结论

  • 两种优化技术下,皮质剂量约束均能显著降低大脑皮质接受28.6 Gy以上剂量的体积,且不损害任何危及器官。
  • 稳健治疗计划比IMRT提供更适形的计划,在皮质保护方面更优。

研究设计与样本

  • 计划研究,将皮质保护目标纳入经典IMRT和稳健治疗计划的优化过程,基于危及器官的剂量体积直方图数据比较有和无皮质保护目标的计划。

主要发现

  • 皮质剂量约束使大脑皮质接受28.6 Gy以上剂量的体积显著减少,与优化技术无关,且对周围危及器官无负面影响。
  • IMRT平均减少超过28.6 Gy阈值的体积19%,稳健治疗计划减少16%。
  • 稳健计划靶区周围剂量梯度更锐利,幅度为3–6%。
  • 将皮质保护纳入优化过程可能降低靶区周围剂量4–8%。

关键数值与推荐

  • 皮质体积评估阈值为28.6 Gy。
  • IMRT平均体积减少19%,稳健治疗计划减少16%。
  • 稳健计划剂量梯度锐利度提高3–6%。
  • 靶区周围剂量降低4–8%。

临床怎么用

  • 在胶质母细胞瘤放疗计划中可考虑加入大脑皮质剂量约束以保护神经认知功能。
  • 稳健治疗计划在皮质保护和剂量适形性方面可能优于经典IMRT。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: To date, patients with glioblastoma still have a bad median overall survival rate despite radiation dose-escalation and combined modality treatment. Neurocognitive decline is a crucial adverse event which may be linked to high doses to the cortex. In a planning study, we investigated the impact of dose constraints to the cerebral cortex and its relation to the organs at risk for glioblastoma patients. METHODS: Cortical sparing was implemented into the optimization process for two planning approaches: classical intensity-modulated radiotherapy (IMRT) and robust treatment planning. The plans with and without objectives for cortex sparing where compared based on dose-volume histograms (DVH) data of the main organs at risk. Additionally the cortex volume above a critical threshold of 28.6 Gy was elaborated. Furthermore, IMRT plans were compared with robust treatment plans regarding potential cortex sparing. RESULTS: Cortical dose constraints result in a statistically significant reduced cerebral cortex volume above 28.6 Gy without negative effects to the surrounding organs at risk independently of the optimization technique. For IMRT we found a mean volume reduction of doses beyond the threshold of 19%, and 16% for robust treatment planning, respectively. Robust plans delivered sharper dose gradients around the target volume in an order of 3 - 6%. Aside from that the integration of cortical sparing into the optimization process has the potential to reduce the dose around the target volume (4 - 8%). CONCLUSIONS: We were able to show that dose to the cerebral cortex can be significantly reduced both with robust treatment planning and IMRT while maintaining clinically adequate target coverage and without corrupting any organ at risk. Robust treatment plans delivered more conformal plans compared to IMRT and were superior in regards to cortical sparing.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Exeli AK, Kellner D, Exeli L, et al. Cerebral cortex dose sparing for glioblastoma patients: IMRT versus robust treatment planning. Radiat Oncol. 2018. PMID: 29409516. doi:10.1186/s13014-018-0953-x

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。